Ellagic acid

Ellagic acid demonstrates antioxidant and anti-inflammatory effects across numerous in vitro studies and animal models. Preliminary antiproliferative activity has been observed in cancer cell lines. Clinical evidence specific to Castanea dentata-derived ellagic acid is absent.

Extensively studied antioxidant and chemopreventive agent; hepatoprotective effects confirmed in animal models of CCl4-induced liver damage; anti-cancer activity in colon, prostate, and breast cancer cell lines

Ellagic acid from black walnut contributes antioxidant and potential anti-cancer effects. It has been studied for chemopreventive properties in colorectal cancer models.

Antioxidant and antiproliferative properties well established. Metabolised to urolithins by gut microbiota for systemic anti-inflammatory effects.

Documented antioxidant and anti-inflammatory properties. Hydrolysis product of ellagitannins with emerging anticancer research interest.

Ellagic acid reduces oxidative vascular damage and atherosclerotic lipid accumulation in cardiovascular disease models. Metabolite of punicalagin with independent cardiovascular benefits. Present in pomegranate extracts.

Ellagic acid demonstrates established antioxidant and anti-inflammatory activity. Hydrolysis product of the ellagitannin fraction.

Antiproliferative activity demonstrated in multiple cancer cell lines. Antioxidant and anti-inflammatory properties well established. Metabolised to urolithins by gut microbiota.

Anti-cancer effects in cell lines (colon, breast). Hepatoprotective in animal models. Released from ellagitannins by gut microbiota.

Ellagic acid is a well-studied polyphenol with established antioxidant and antiproliferative activity. Contributes to the astringent and protective properties of strawberry leaf preparations.